IN2014DN03247A - - Google Patents
Info
- Publication number
- IN2014DN03247A IN2014DN03247A IN3247DEN2014A IN2014DN03247A IN 2014DN03247 A IN2014DN03247 A IN 2014DN03247A IN 3247DEN2014 A IN3247DEN2014 A IN 3247DEN2014A IN 2014DN03247 A IN2014DN03247 A IN 2014DN03247A
- Authority
- IN
- India
- Prior art keywords
- progestin
- estrogen
- disclosed
- composition
- transdermal delivery
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 6
- 239000000583 progesterone congener Substances 0.000 abstract 6
- 239000003963 antioxidant agent Substances 0.000 abstract 3
- 230000003078 antioxidant effect Effects 0.000 abstract 3
- 235000006708 antioxidants Nutrition 0.000 abstract 3
- 229940011871 estrogen Drugs 0.000 abstract 3
- 239000000262 estrogen Substances 0.000 abstract 3
- 238000001794 hormone therapy Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000037317 transdermal delivery Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555546P | 2011-11-04 | 2011-11-04 | |
| US201261645778P | 2012-05-11 | 2012-05-11 | |
| PCT/US2012/063314 WO2013067346A1 (en) | 2011-11-04 | 2012-11-02 | Dermal delivery compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03247A true IN2014DN03247A (es) | 2015-05-22 |
Family
ID=47278507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3247DEN2014 IN2014DN03247A (es) | 2011-11-04 | 2012-11-02 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9364487B2 (es) |
| EP (1) | EP2773333B1 (es) |
| JP (1) | JP6316749B2 (es) |
| KR (1) | KR20140088199A (es) |
| CN (1) | CN103957899A (es) |
| AU (1) | AU2012332254B2 (es) |
| BR (1) | BR112014010670A2 (es) |
| CA (1) | CA2854164C (es) |
| EA (1) | EA026664B1 (es) |
| ES (1) | ES2762460T3 (es) |
| HK (1) | HK1200317A1 (es) |
| IL (1) | IL232258A0 (es) |
| IN (1) | IN2014DN03247A (es) |
| MX (1) | MX353713B (es) |
| PH (1) | PH12014501000A1 (es) |
| WO (1) | WO2013067346A1 (es) |
| ZA (1) | ZA201402988B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| GB2521632B (en) * | 2013-12-23 | 2020-12-16 | Linscott Goode Steven | Vermin control compositions |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| US9844558B1 (en) | 2015-04-30 | 2017-12-19 | Amag Pharmaceuticals, Inc. | Methods of reducing risk of preterm birth |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017059070A1 (en) | 2015-09-29 | 2017-04-06 | Amag Pharmaceuticals, Inc. | Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| MX2020004491A (es) * | 2017-10-30 | 2020-08-13 | Kaken Pharma Co Ltd | Preparacion externa para tratar tinea unguium. |
| JP7220473B2 (ja) * | 2017-10-30 | 2023-02-10 | 帝國製薬株式会社 | 経皮投与製剤 |
| CN112739383B (zh) * | 2018-09-19 | 2024-03-15 | 埃斯普投资有限公司 | 过氧化物稳定的聚合物组合物及其制备方法和应用 |
| CN113455506A (zh) * | 2021-06-29 | 2021-10-01 | 无锡宏霸医疗科技有限公司 | 一种适用于日化产品的水相除臭去味剂及其制备方法 |
| FR3125684A1 (fr) * | 2021-07-28 | 2023-02-03 | Roquette Freres | Composition de dianhydrohexitols stables a l’oxydation et contenant un ester d’acide gallique |
| CN114259498B (zh) * | 2021-12-02 | 2023-04-28 | 南通联亚药业股份有限公司 | 一种包含去氧孕烯和炔雌醇的药物组合物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5554381A (en) * | 1993-08-09 | 1996-09-10 | Cygnus, Inc. | Low flux matrix system for delivering potent drugs transdermally |
| FR2739031B1 (fr) * | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique |
| DE19700913C2 (de) * | 1997-01-14 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Hormonen |
| IT1294748B1 (it) * | 1997-09-17 | 1999-04-12 | Permatec Tech Ag | Formulazione per un dispositivo transdermico |
| GB9720470D0 (en) | 1997-09-25 | 1997-11-26 | Ethical Pharmaceuticals South | Inhibition of crystallization in transdermal devices |
| WO2001001990A1 (en) * | 1999-07-01 | 2001-01-11 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive preparation for percutaneous absorption |
| US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
| BR0015802B1 (pt) * | 1999-11-24 | 2014-04-29 | Agile Therapeutics Inc | Sistema de administração de contraceptivo transdérmico, e, método para produzir um sistema de administração de contraceptivo transdérmico |
| US7045145B1 (en) | 1999-11-24 | 2006-05-16 | Agile Therapeutics, Inc. | Transdermal contraceptive delivery system and process |
| DE50115609D1 (de) * | 2000-02-17 | 2010-10-14 | Basf Se | Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen |
| JP4422430B2 (ja) * | 2003-05-14 | 2010-02-24 | 帝國製薬株式会社 | エストロゲン及び／又はプロゲストゲン含有外用貼付剤 |
| WO2006036899A2 (en) * | 2004-09-27 | 2006-04-06 | Corium International, Inc. | Transdermal systems for the delivery of estrogens and progestins |
| CA2604943C (en) * | 2005-04-15 | 2013-09-17 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| AU2006249349B2 (en) * | 2005-05-26 | 2012-01-12 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and methods of making and using the same |
| US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
| DE102006050558B4 (de) * | 2006-10-26 | 2009-03-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution |
| TW200831139A (en) * | 2006-11-29 | 2008-08-01 | Wyeth Corp | Estrogen/SERM and estrogen/progestin bi-layer tablets |
| US8246978B2 (en) | 2007-07-10 | 2012-08-21 | Agile Therapeutics, Inc. | Dermal delivery device with reduced loss of its volatile components |
| US20100178323A1 (en) | 2007-07-10 | 2010-07-15 | Agis Kydonieus | Dermal Delivery Device |
| WO2009009651A1 (en) | 2007-07-10 | 2009-01-15 | Agile Therapeutics, Inc. | Dermal delivery device with ultrasonic weld |
| WO2009142699A1 (en) * | 2008-05-19 | 2009-11-26 | The Procter & Gamble Company | Treatment of heart failure in women |
| EP2410859A4 (en) * | 2009-03-27 | 2013-03-13 | Agile Therapeutics Inc | TRANSDERMAL ADMINISTRATION |
-
2012
- 2012-11-02 PH PH1/2014/501000A patent/PH12014501000A1/en unknown
- 2012-11-02 EA EA201400543A patent/EA026664B1/ru not_active IP Right Cessation
- 2012-11-02 IN IN3247DEN2014 patent/IN2014DN03247A/en unknown
- 2012-11-02 EP EP12794803.2A patent/EP2773333B1/en active Active
- 2012-11-02 JP JP2014540132A patent/JP6316749B2/ja active Active
- 2012-11-02 HK HK15100698.8A patent/HK1200317A1/xx unknown
- 2012-11-02 ES ES12794803T patent/ES2762460T3/es active Active
- 2012-11-02 CA CA2854164A patent/CA2854164C/en active Active
- 2012-11-02 BR BR112014010670A patent/BR112014010670A2/pt not_active IP Right Cessation
- 2012-11-02 CN CN201280054080.8A patent/CN103957899A/zh active Pending
- 2012-11-02 WO PCT/US2012/063314 patent/WO2013067346A1/en not_active Ceased
- 2012-11-02 MX MX2014005294A patent/MX353713B/es active IP Right Grant
- 2012-11-02 AU AU2012332254A patent/AU2012332254B2/en not_active Ceased
- 2012-11-02 US US13/667,632 patent/US9364487B2/en active Active
- 2012-11-02 KR KR1020147014699A patent/KR20140088199A/ko not_active Ceased
-
2014
- 2014-04-24 ZA ZA2014/02988A patent/ZA201402988B/en unknown
- 2014-04-27 IL IL232258A patent/IL232258A0/en unknown
-
2016
- 2016-05-11 US US15/151,966 patent/US20160250226A1/en not_active Abandoned
-
2018
- 2018-07-25 US US16/045,338 patent/US20180325916A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180325916A1 (en) | 2018-11-15 |
| EA201400543A1 (ru) | 2014-09-30 |
| EP2773333B1 (en) | 2019-10-02 |
| ZA201402988B (en) | 2015-11-25 |
| CA2854164C (en) | 2021-04-13 |
| IL232258A0 (en) | 2014-06-30 |
| WO2013067346A1 (en) | 2013-05-10 |
| KR20140088199A (ko) | 2014-07-09 |
| US20160250226A1 (en) | 2016-09-01 |
| MX2014005294A (es) | 2014-09-22 |
| BR112014010670A2 (pt) | 2017-05-09 |
| US9364487B2 (en) | 2016-06-14 |
| JP6316749B2 (ja) | 2018-04-25 |
| AU2012332254A1 (en) | 2014-05-15 |
| PH12014501000A1 (en) | 2014-06-09 |
| HK1201152A1 (en) | 2015-08-28 |
| HK1200317A1 (en) | 2015-08-07 |
| CN103957899A (zh) | 2014-07-30 |
| EA026664B1 (ru) | 2017-05-31 |
| CA2854164A1 (en) | 2013-05-10 |
| US20130116222A1 (en) | 2013-05-09 |
| JP2014532719A (ja) | 2014-12-08 |
| AU2012332254B2 (en) | 2017-06-22 |
| EP2773333A1 (en) | 2014-09-10 |
| MX353713B (es) | 2018-01-24 |
| NZ624117A (en) | 2016-02-26 |
| ES2762460T3 (es) | 2020-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03247A (es) | ||
| MX365818B (es) | Formulaciones y terapias de reemplazo hormonal de combinacion naturales. | |
| MX2020013533A (es) | Formulaciones y terapias de reemplazo de combinacion de hormonas naturales. | |
| PH12013500481A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12012502419A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12015501737B1 (en) | Androgen receptor modulators and uses thereof | |
| BR112014031824A2 (pt) | terapias de reposição hormonal transdérmica | |
| PH12014501351A1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| HK1211317A1 (en) | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders | |
| GB201200062D0 (en) | Estradiol oromucosal liquid compositions | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| MX2012007933A (es) | Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. | |
| CL2009001011A1 (es) | Uso del compuesto 21-metoxi-17a-acetoxi-11ß-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona (cdb-4124) para tratar el cancer de mama; y uso de la combinacion de cdb-4124 con un inhibidor de aromatasa. | |
| MX2013004693A (es) | Composiciones de aripiprazol y metodos para su suministro transdermico. | |
| MX367596B (es) | Tratamientos transdermicos de sustitucion hormonal. | |
| NZ714288A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| TN2014000059A1 (en) | Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases | |
| MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| MX2014008693A (es) | Administracion transdermica de hormonas. | |
| MX2016004392A (es) | Sistema de doble agente de ruptura para reducir daño a la formacion durante la fracturacion. | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| NZ738063A (en) | Stable povidone-iodine compositions | |
| WO2012031999A3 (en) | Low-dose transdermal patches with high drug release | |
| NZ620005A (en) | Pharmaceutical composition comprising ebastine and fluticasone |